<DOC>
	<DOCNO>NCT00771329</DOCNO>
	<brief_summary>Phase I study design determine safety tolerability single dose BIIB023 administer intravenously versus placebo subject RA .</brief_summary>
	<brief_title>BIIB023 ( Anti-TWEAK ) Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis adult onset RA ( functional class IIII ) least 6 month Must treat tolerate Methotrexate ( 525 mg/week ) 3 month , stable dose least 4 week Must least 4 swollen tender joint due rheumatoid arthritis History recurrent infection require antibiotic treatment within 12 month Serious local infection systemic infection within 3 month Suffering rheumatic autoimmune disease RA History cancer , heart failure , kidney disease , liver disease , HIV infection , tuberculosis serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>